1. Introduction {#sec1-scipharm-84-00484}
===============

Effective antibiotics are needed to combat the growing bacterial resistance \[[@B1-scipharm-84-00484]\]. Cephalosporins are an important class of antimicrobials with a broad-spectrum of activity and a favourable safety profile \[[@B2-scipharm-84-00484]\]. The traditional approach to develop new antibiotics involves antimicrobial screening of natural products \[[@B3-scipharm-84-00484],[@B4-scipharm-84-00484]\]. However, building new analogues of those antibiotics which are currently in use is more financially feasible because these analogues tend to have similar solubility, protein binding, and toxicity as the parent compounds \[[@B5-scipharm-84-00484]\].

Acylation reactions enabled the development of various generations of cephalosporins \[[@B6-scipharm-84-00484]\]. In addition, cephalosporins that contain nitrogen nucleophiles can be further acylated in order to modulate their antimicrobial activity, improve their solubility, and introduce fluorescent tags \[[@B7-scipharm-84-00484],[@B8-scipharm-84-00484],[@B9-scipharm-84-00484]\]. Such acylations have been accomplished utilizing acid chlorides, acid anhydrides, and ethyl chloroformate \[[@B7-scipharm-84-00484],[@B10-scipharm-84-00484],[@B11-scipharm-84-00484]\].

*N*-acylbenzotriazoles are advantageous acylating agents showing numerous merits over acid chlorides because: (i) they are usually isolated in high yields; (ii) they form crystals easily; (iii) they are stable in air; and (iv) chirality is preserved during the course of their preparation and reaction. These carboxylic acid surrogates are widely used when the corresponding acid chlorides are unstable or difficult to prepare \[[@B12-scipharm-84-00484]\].

Amino acid conjugates of quinolone, metronidazole, and sulfadiazine antibiotics were recently synthesized in good yields using the benzotriazole methodology \[[@B13-scipharm-84-00484]\]. In the current work, cephalexin ([Figure 1](#scipharm-84-00484-f001){ref-type="fig"}), which is a first generation cephalosporin on the World Health Organization's list of essential medicines, was selected for further acylation with a variety of *N*-acylbenzotriazoles (**3a**--**k′**). *N*-acylcephalexins (**4a**--**k′**) were obtained in pure form in high yields by a simple work-up and their antibacterial activity was evaluated \[[@B4-scipharm-84-00484]\].

2. Materials and Methods {#sec2-scipharm-84-00484}
========================

2.1. Chemistry {#sec2dot1-scipharm-84-00484}
--------------

Starting materials and solvents were purchased from common commercial sources and used without further purification. Melting points were determined on the Fisher Melting Apparatus, (Pittsburgh, PA, USA). ^1^H-NMR (400 MHz) and ^13^C-NMR (100 MHz) spectra were recorded on a Bruker 400 MHz NMR Spectrometer (Bruker, Fällanden, Switzerland) in DMSO-*d*~6~. *J* values are given in Hz, using tetramethylsilane (TMS) as the internal standard at the Faculty of Science, Zagazig University. ^1^H and ^13^C NMR spectra of Compounds **7d**--**j** and **8a**--**j** can be found in [Supplementary Figures S1 and S2](#app1-scipharm-84-00484){ref-type="app"}. Elemental analyses were performed on the Carlo Erba-1106 (Thermo Fisher Scientific Inc., Waltham, MA, USA) instrument at the Regional Center for Mycology & Biotechnology, Al-Azhar University, Cairo. The reactions were followed by Thin Layer Chromatography (TLC) (silica gel, aluminum sheets 60 F254, Merck, Darmstadt, Germany). The purity of the newly synthesized compounds was assessed by TLC and elemental analysis.

*Procedure for the Synthesis of 4-methyl-2-(3,4,5trimethoxybenzamido) thiazole-5-carboxylic acid* (**2j**): Thiourea (0.152 g, 2 mmol) was refluxed in absolute ethanol with ethyl 2-chloroacetoacetate (0.28 mL, 2 mmol) for 4 h. At the end of the reaction, the solvent was evaporated and 5 mL of H~2~O was added, followed by neutralization with NH~4~OH to give compound **5** (0.32 g, off-white microcrystals). Compound (**5**) (0.32 g, 1.7 mmol) was subjected to hydrolysis with NaOH (0.272 g, 6.8 mmol) in (THF-H~2~O 3:1) under overnight reflux. At the end of the reaction, THF was evaporated and the pH was adjusted to 6--7 with HCl. After it was filtered, the solid was washed with water and then dried to give compound (**6**) (0.21 g). Compound (**6**) (0.21 g, 1.3 mmol) was refluxed with compound (**3g**) (0.4 g, 1.3 mmol) in dioxane in the presence of one equivalent TEA (0.18 mL). At the end of the reaction, the solvent was evaporated; ethylacetate was added and washed with diluted HCl. The organic layer was then dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to give compound (**2j**) (0.40 g, 90%).

*Procedure for the Synthesis of N-acylbenzotriazoles* (**3a**--**k′**): To 0.95 g BtH (8 mmol) dissolved in 50 mL CH~2~Cl~2~, 0.14 mL SOCl~2~ (2 mmol) were added. The mixture was stirred at 25 °C for 30 min, followed by the addition of the corresponding acid **2a**--**k′** (2 mmol) and the reaction was allowed to stir for an additional 3 h at 25 °C. The reaction was diluted with CH~2~Cl~2~ (50 mL) and the organic layer was washed with saturated Na~2~CO~3~ (20 mL, 3×), H~2~O (20 mL, 2×), and brine (10 mL, 1×). The organic layer was dried over anhydrous sodium sulfate. Hexane (50 mL) was added to the filtrate, then the solid obtained was dried under vacuum to give compounds **3a**--**k′**.

*Procedure for the Synthesis of N-acylcephalexines* **4a**--**k′**: Cephalexin sodium salt (0.37 g, 1 mmol) was dissolved in water (1 mL) and added to the solution of the corresponding *N*-acylbenzotriazoles (1 mmol) in CH~3~CN (7 mL). The mixture was stirred for 6--20 h (until complete consumption of *N*-acylbenzotriazole as monitored by TLC). The pH was adjusted to 5 using 2 N HCl, and the solvent was evaporated under reduced pressure. The residue was then extracted with ethyl acetate (20 mL, 2×) and the organic layer was washed with 4 N HCl (10 mL, 3×), water (10 mL, 1×), and brine (10 mL, 1×) then dried over anhydrous sodium sulfate. Hexane (10 mL) was added to the filtrate and the solution was left overnight in the freezer to give the desired products **4a**--**k′**.

*(1H-Benzo\[d\]\[1,2,3\]triazol-1-yl)(phenyl)methanone* (**3d**): White microcrystals; yield: (0.42 g, 94%); m.p. 111--112 °C, lit. (110--112 °C) \[[@B14-scipharm-84-00484]\]. ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 8.33--8.28 (m, 2H, Ar-H), 8.13--8.10 (m, 2H,Ar-H), 7.85--7.76 (m, 2H, Ar-H), 7.68--7.63 (m, 3H, Ar-H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 166.5 (C=O), 145.2 (C-N=N), 133.5 (Ar-C), 131.7 (Ar-C), 131.5 (Ar-C), 131.3 (Ar-C), 130.7 (Ar-C), 128.3 (Ar-C), 126.6 (Ar-C), 120.0 (Ar-C), 114.4 (Ar-C).

*(1H-Benzo\[d\]\[1,2,3\]triazol-1-yl)(pyridin-3-yl)methanone* (**3e**): White microcrystals; yield: (0.42 g, 94%); m.p. 101--102 °C, lit. (101--102 °C) \[[@B15-scipharm-84-00484]\]. ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.22 (s, 1H, N=CH-C-C=O), 8.90 (d, *J* = 6.5 Hz, 1H, Ar-H), 8.50--8.48 (m, 1H, Ar-H), 8.33 (dd, *J* = 17.6 Hz, 8.4 Hz, 2H,Ar-H), 7.86 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.71--7.66 (m, 2H, Ar-H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 165.3 (C=O), 153.3 (CH-N), 151.3 (N=CH-CC=O), 145.2 (C-N=N), 138.8 (Ar-C), 131.4 (Ar-C), 130.9 (Ar-C), 128.0 (Ar-C), 126.8 (Ar-C), 123.3 (Ar-C), 120.1 (Ar-C), 114.3 (Ar-C).

*(1H-Benzo\[d\]\[1,2,3\]triazol-1-yl)(3-nitrophenyl)methanone* (**3f**): White microcrystals; yield: (0.48 g, 90%); m.p. 159--162 °C, lit. (155.0--156 °C) \[[@B16-scipharm-84-00484]\]. ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 8.91 (t, *J* = 2.0 Hz, 1H, Ar-H), 8.60--8.57 (m, 1H, Ar-H), 8.54--8.51 (m, 1H, Ar-H), 8.34 (dd, *J* = 16.0, 8.0 Hz, 2H, Ar-H), 7.95 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.89--7.85 (m, 1H, Ar-H), 7.72--7.67 (m,1H, Ar-H). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 164.7 (C=O), 147.3 (C-NO~2~), 145.2 (C-N=N),137.2 (C=CH-CH=C-NO~2~), 133.2 (Ar-C), 131.5 (Ar-C), 131.0 (Ar-C), 130.1(Ar-C), 127.5 (Ar-C), 126.8 (Ar-C), 125.9 (Ar-C), 120.1 (Ar-C), 114.4 (Ar-C).

*(1H-Benzo\[d\]\[1,2,3\]triazol-1-yl)(3,4,5-trimethoxyphenyl)methanone* (**3g**): White microcrystals; yield: (0.6 g, 96%); m.p. 126--128 °C, (126--128 °C) \[[@B17-scipharm-84-00484]\]. ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 8.28 (d, *J* = 10.8 Hz, 2H, Ar-H), 7.83 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.65 (t, *J* = 7.8 Hz, 1H, Ar-H), 7.47 (s, 2H, Ar-H), 3.86 (s, 6H, *m*-(OCH~3~)), 3.82 (s, 3H, *p*-(OCH~3~)).

*(S)-N-(1-(1H-Benzo\[d\]\[1,2,3\]triazol-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-4-methylbenzenesulfonamide* (**3h**): Brown microcrystals; yield: (0.80 g, 87%); m.p. 175--176 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 10.77 (s, 1H, NH), 8.90 (d, *J =* 8.4 Hz, 1H, Ar-H), 8.23 (d, *J =* 8.0 Hz, 1H, Ar-H), 8.03 (d, *J =* 8.4 Hz, 1H, Ar-H), 7.77 (t, *J =* 7.8 Hz, 1H, Ar-H), 7.61 (t, *J =* 7.6 Hz, 1H, Ar-H), 7.45 (d, *J =* 7.6 Hz, 1H, Ar-H), 7.27(d, *J =* 7.2 Hz, 2H, Ar-H), 7.24 (s, 1H, NH-SO~2~), 7.13 (s, 1H, [CH]{.ul}-NH-C), 7.02 (t, *J =* 7.4 Hz, 1H, Ar-H), 6.92 (t, *J =* 7.4 Hz, 1H, Ar-H), 6.87 (d, *J =* 8 Hz, 2H, Ar-H), 5.55 (dd, *J =* 8.8, 5.6 Hz, 1H, [CH]{.ul}-NH-SO~2~), 3.41 (dd, *J =* 14.4, 5.6 Hz, 1H, [CH~2~]{.ul}-CH-NH), 3.12 (dd, *J =* 14.4, 8.8 Hz, 1H, [CH~2~]{.ul}-CH-NH), 2.06 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 171.2 (C=O), 145.4 (C-N=N), 142.4 (=C-SO~2~), 136.9 (Ar-C), 136.1 (Ar-C), 131.0 (Ar-C), 130.2 (Ar-C), 128.9 (Ar-C), 126.7 (Ar-C), 126.6 (Ar-C), 126.0 (Ar-C), 124.5 (Ar-C), 120.9 (Ar-C), 120.1 (Ar-C), 118.5 (Ar-C), 117.9 (Ar-C), 113.8 (Ar-C), 111.4 (Ar-C), 108.0 (Ar-C), 55.7 (CH-NH-SO~2~), 28.2 (CH~2~-CH-NH), 20.7 (CH~3~). Anal. Calcd. for C~24~H~21~N~5~O~3~S: C, 62.73; H, 4.61; N, 15.24; S, 6.98; found: C, 62.85; H, 4.68; N, 15.37; S, 7.02.

*N-(2-(1H-Benzo\[d\]\[1,2,3\]triazole-1-carbonyl)phenyl)-4-methylbenzenesulfonamide* (**3i**): White microcrystals; yield: (0.70 g, 89%); m.p. 148--150 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 10.06 (s, 1H, NHSO~2~), 8.29 (t, *J =* 8.2 Hz, 2H, Ar-H), 7.85 (t, *J =* 8.2 Hz, 1H,Ar-H), 7.78 (dd, *J =* 7.6, 1.6 Hz, 1H, Ar-H), 7.66 (t, *J =* 7.2 Hz, 1H,Ar-H), 7.55--7.50 (m, 1H,Ar-H), 7.45 (d, *J =* 8.0 Hz, 2H, Ar-H), 7.38 (t, *J =* 7.6 Hz, 1H, Ar-H), 7.24 (d, *J =* 8.0 Hz, 2H, Ar-H), 7.04 (d, *J =* 8.4 Hz, 1H, Ar-H), 2.27 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 165.7 (C=O), 145.4 (C-N=N), 143.2 (C-NH), 136.2 (Ar-C), 135.3 (Ar-C), 132.6 (Ar-C), 131.3 (Ar-C), 131.3 (Ar-C), 130.5 (Ar-C), 129.4 (Ar-C), 128.6 (Ar-C), 126.6 (Ar-C), 126.4 (Ar-C), 125.5 (Ar-C), 125.2 (Ar-C), 119.9 (Ar-C), 114.3 (Ar-C), 20.8 (CH~3~). Anal. Calcd. for C~20~H~16~N~4~O~3~S: C, 61.21; H, 4.11; N, 14.28; S, 8.17; found: C, 61.39; H, 4.17; N, 14.45; S, 8.29.

*N-(5-(1H-Benzo\[d\]\[1,2,3\]triazole-1-carbonyl)-4-methylthiazol-2-yl)-3,4,5-trimethoxybenzamide* (**3j**): White microcrystals; yield: (0.74 g, 82%); m.p. 107--110 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 8.29 (d, *J =* 8.4 Hz, 2H, Ar-H), 7.83 (t, *J* = 6.8 Hz, 1H, Ar-H), 7.66 (t, *J* = 7.0 Hz, 1H, Ar-H), 7.47 (s, 2H, Ar-H), 7.14 (s, 1H, NH), 3.86 (s, 6H, *m*-(OCH~3~)), 3.82 (s, 3H, *p*-(OCH~3~)) 1.17 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 165.80 (C=O), 152.42 (C=O), 145.2 (N-C-CH~3~), 142.3 (C-OCH~3~), 131.9 (Ar-C), 130.7 (Ar-C), 128.2 (Ar-C), 127.4 (Ar-C), 126.6 (Ar-C), 126.2 (Ar-C), 125.7 (Ar-C), 120.0 (Ar-C), 114.3 (Ar-C), 109.4 (Ar-C), 60.3 (p-OCH~3~), 56.2 (m-OCH~3~), 14.1 (CH~3~). Anal. Calcd. for C~21~H~19~N~5~O~5~S: C, 55.62; H, 4.22; N, 15.44; S, 7.07.; found: C, 55.78; H, 4.30; N, 15.61; S, 7.15.

*(S)-N-(1-(1H-Benzo\[d\]\[1,2,3\]triazole-1-yl)-1-oxopropan-2-yl)-4-methylbenzenesulfonamide* (**3k**): White microcrystals; yield: (0.62 g, 90%); m.p. 142--144 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 8.78 (d, *J* = 7.8 Hz, 1H, NH-SO~2~), 8.26 (d, *J* = 8.2 Hz, 1H, Ar-H), 8.03 (d, *J* = 8.2 Hz, 1H, Ar-H), 7.78 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.63 (t, *J* = 7.6 Hz, 1H, Ar-H), 7.57 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.16 (d, *J* = 8.0 Hz, 2H, Ar-H), 5.35--5.28 (m, 1H, NH-[CH]{.ul}-CH~3~), 2.18 (s, 3H, *p*-CH~3~), 1.45(d, *J* = 6.8 Hz, 3H, NH-CH-[CH~3~]{.ul}). Anal. Calcd. for C~16~H~16~N~4~O~3~S: C, 55.80; H, 4.68; N, 16.27; S, 9.31; found: C, 55.96; H, 4.76; N, 16.43; S, 9.41.

*(RS)-N-(1-(1H-Benzo\[d\]\[1,2,3\]triazole-1-yl)-1-oxopropan-2-yl)-4-methylbenzenesulfonamide* (**3k, 3k′**): White microcrystals; yield: (0.62 g, 90%); m.p. 142--144 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 8.78 (d, *J* = 8.4 Hz, 1H, NH-SO~2~), 8.27(d, *J* = 8.4 Hz, 1H, Ar-H), 8.03 (d, *J* = 8.4 Hz, 1H, Ar-H), 7.79 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.63 (t, *J* = 8.0 Hz, 1H, Ar-H), 7.57 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.16 (d, *J* = 8.0 Hz, 2H, Ar-H), 5.35--5.27 (m, 1H, NH-[CH]{.ul}-CH~3~), 2.18 (s, 3H, *p*-CH~3~), 1.44 (d, *J* = 6.8 Hz, 3H NH-CH-[CH~3~]{.ul}). Anal. Calcd. for C~16~H~16~N~4~O~3~S: C, 55.80; H, 4.68; N, 16.27; S, 9.31; found: C, 55.94; H, 4.71; N, 16.60; S, 9.44.

*(6R,7R)-7-((R)-2-(2-(((Benzyloxy)carbonyl)amino)acetamido)-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4a**): White microcrystals; yield: (0.47 g, 87%); m.p. 210--212 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 13.21 (s, 1H, COOH), 9.35 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.53 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.49--7.43 (m, 3H, [NH]{.ul}-CO-O-, 2Ar-H), 7.35--7.24 (m, 8H, Ar-H), 5.70 (d, *J* = 8.4 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.62 (dd, *J* = 8.4, 4.8 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.03 (s, 2H, Ph-[CH~2~]{.ul}-O-), 4.96 (d, *J* = 4.8 Hz, 1H, -[CH]{.ul}-S-), 3.73 (d, *J* = 6.0 Hz, 2H, NH-[CH~2~]{.ul}-CO-), 3.46 (d, *J* = 18.0 Hz, 1H, -S-[CH~2~]{.ul}-), 3.28 (d, *J* = 18.0 Hz, 1H, -S-[CH~2~]{.ul}-), 1.98 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.6 ([CO]{.ul}-NH-CH), 168.7 ([CO]{.ul}-NH-CH-Ph), 163.9 ([CO]{.ul}-N-), 163.5 (COOH), 156.5([CO]{.ul}-O-CH~2~), 138.1 (Ar-C), 137.1 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 127.6 (Ar-C), 127.0 (CH~3~-[C]{.ul}=C), 122.8 (-C=[C]{.ul}-COOH), 65.4 (O-[CH~2~]{.ul}-Ph), 58.4 (-[CH]{.ul}-S-), 57.1 ([CH]{.ul}-CH-S-), 55.4 ([CH]{.ul}(CO)Ph), 43.3 ([CH~2~]{.ul}-NH-CO-O-), 28.9 (-S-[CH~2~]{.ul}-), 19.4 (CH~3~). Anal. Calcd. for C~26~H~26~N~4~O~7~S: C, 57.98; H, 4.87; N, 10.4; S, 5.95; found: C, 58.13; H, 4.91; N, 10.62; S, 6.04.

*(6R,7R)-7-((R)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-phenylpropanamido)-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4b**): White microcrystals; yield: (0.54 g, 86%); m.p. 216--218 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.37 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.83 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.56 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)CH~2~-Ph), 7.40--7.19 (m, 15H, Ar-H), 5.74 (d, *J* = 8.4 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.63 (dd, *J* = 8.4, 4.4 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 4.96 (d, *J* = 4.4 Hz, 1H, -[CH]{.ul}-S-), 4.94 (s, 2H, Ph-[CH~2~]{.ul}-O-), 4.50--4.45 (m, 1H, NH-[CH]{.ul}(CO)-CH~2~-Ph), 3.46 (d, *J* = 18.4 Hz,1H, -S-[CH~2~]{.ul}-), 3.25 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 2.96 (dd, *J* = 13.6, 4.0 Hz, 1H, NH-CH(CO)-[CH~2~]{.ul}-Ph), 2.71 (dd, *J* = 13.6, 10.4 Hz, 1H, NH-CH(CO)-[CH~2~]{.ul}Ph ), 1.97 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 171.2 ([CO]{.ul}-NH-CH(CO)-Ph), 170.6 (CO-NH-CH[(CO)]{.ul}-Ph), 163.9 ([CO]{.ul}-N-), 163.5 (COOH), 155.8 ([CO]{.ul}-O-CH~2~), 138.3 (Ar-C), 137.9 (Ar-C), 137.0 (Ar-C), 129.8 (Ar-C), 129.3(Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 128.0 (Ar-C), 127.7 (Ar-C), 127.4 (Ar-C), 126.8 (Ar-C), 126.2 (Ar-C), 125.8 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 65.2 (O-[CH~2~]{.ul}-Ph), 58.4 (-[CH]{.ul}-S-), 57.2 ([CH]{.ul}(CO)-CH-S-), 56.0 ([CH]{.ul}(CO)Ph), 55.3 ([CH]{.ul}(CO)-NH-CO-O-), 28.9 (-S-[CH~2~]{.ul}-), 19.4 (CH-[CH~2~]{.ul}-Ph), 13.9 (CH~3~). Anal. Calcd. for C~33~H~32~N~4~O~7~S: C, 63.04; H, 5.13; N, 8.91; S, 5.1; found: C, 63.21; H, 5.19; N, 9.04; S, 5.18.

*(6R,7R)-7-((R)-2-((S)-2-(((benzyloxy)carbonyl)amino)-3-(1H-indol-3-yl)propanamido)-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4c**): White microcrystals; yield: (0.56 g, 84%); m.p. 168--170 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 13.16 (s, 1H, COOH), 10.80 (s, 1H, NH), 9.34 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.75 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.65 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CO-O), 7.46 (d, *J* = 8.4 Hz, 1H, Ar-H), 7.37--7.22 (m, 11H, Ar-H), 7.14 (s, 1H, =[CH]{.ul}-NH), 7.05 (t, *J* = 7.4 Hz, 1H, Ar-H), 6.95 (t, *J* = 7.4 Hz, 1H, Ar-H), 5.71 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.65 (dd, *J* = 8.0, 4.4 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 4.99 (d, *J* = 4.4 Hz, 1H, -[CH]{.ul}-S-), 4.95 (s, 2H, Ph-[CH~2~]{.ul}-O-), 4.53--4.47 (m, 1H, [CH]{.ul}-NH-CO-O-), 3.48 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 3.28 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 3.09 (dd, *J* = 14.0, 4.4 Hz, 1H, [CH~2~]{.ul}-CH-NH-CO-O-), 2.91 (dd, *J* = 14.0, 9.6 Hz, 1H, [CH~2~]{.ul}-CH-NH-CO-O-), 1.99 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 171.6 ([CO]{.ul}-NH-CH(CO)-Ph), 170.6 (CO-NH-CH[(CO)]{.ul}-Ph), 163.9 ([CO]{.ul}-N-), 163.5 (COOH), 155.8 ([CO]{.ul}-O-CH~2~), 138.2 (Ar-C), 137.0 (Ar-C), 136.1 (Ar-C), 129.8(Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 127.4 (Ar-C), 127.3 (Ar-C), 126.9(Ar-C), 124.0 (CH~3~-[C]{.ul}=C), 122.8 (-C=[C]{.ul}-COOH), 120.8 (Ar-C), 118.7 (Ar-C), 118.2 (Ar-C), 111.2 (Ar-C), 109.9 (Ar-C), 65.3 (O-[CH~2~]{.ul}-Ph), 58.5 (-[CH]{.ul}-S-), 57.2 ([CH]{.ul}(CO)-CH-S-), 55.5 ([CH]{.ul}(CO)Ph), 55.4 ([CH]{.ul}(CO)-NH-CO-O-), 28.9 (-S-[CH~2~]{.ul}-), 27.9 ([CH~2~]{.ul}-CH-NH-(CO)-O-), 19.4 (CH~3~). Anal. Calcd. for C~35~H~33~N~5~O~7~S: C, 62.96; H, 4.98; N, 10.49; S, 4.8; found: C, 63.14; H, 5.06; N, 10.67; S, 4.91.

*(6R,7R)-7-((R)-2-benzamido-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4d**): Yellow microcrystals; yield: (0.38 g, 84%); m.p. 132--134 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 13.11 (s, 1H, COOH), 9.27 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.86 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.92 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.59--7.44 (m, 5H, Ar-H), 7.37--7.28 (m, 3H, Ar-H), 5.89 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.66 (dd, *J* = 8.0, 4.4 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.00 (d, *J* = 4.4 Hz, 1H, -[CH]{.ul}-S-), 3.48 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 3.28 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 1.99 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.7 (CO-NH-CH[(CO)]{.ul}-Ph), 166.2 (([CO]{.ul})-Ph), 163.9 ([CO]{.ul}-N-), 163.4 (COOH), 137.7 (Ar-C), 133.8 (Ar-C), 132.8 (Ar-C), 131.4 (Ar-C), 129.7 (Ar-C), 129.2 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 127.7 (Ar-C), 127.5 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 58.5 (-[CH]{.ul}-S-), 57.1 ([CH]{.ul}(CO)Ph), 56.5 ([CH]{.ul}(CO)-CH-S-), 28.9 (-S-[CH~2~]{.ul}-), 19.3 (CH~3~). Anal. Calcd. for C~23~H~21~N~3~O~5~S: C, 61.18; H, 4.69; N, 9.31; S, 7.1; found: C, 61.42; H, 4.76; N, 9.43; S, 7.19.

*(6R,7R)-3-methyl-7-((R)-2-(nicotinamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4e**): White microcrystals; yield: (0.37 g, 82%); m.p. 200--202 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.29 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 9.21 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 9.04 (s, 1H, Ar-H), 8.70 (dd, *J* = 4.8, 1.6 Hz, 1H, Ar-H), 8.27--8.24 (m, 1H, Ar-H), 7.54 (d, *J* = 6.8 Hz, 2H, Ar-H), 7.51--7.48 (m, 1H, Ar-H), 7.38--7.29 (m, 3H, Ar-H ), 5.90 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.59 (dd, *J* = 8.4, 4.8 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 4.94 (d, *J* = 4.4 Hz, 1H, -[CH]{.ul}-S-), 3.42 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 3.18 (d, *J* = 18.4Hz, 1H, -S-[CH~2~]{.ul}-), 1.95 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 171.1 (CO-NH-CH[(CO)]{.ul}-Ph), 165.5 ([CO]{.ul}-NH-CH(CO)-Ph), 164.9 ([CO]{.ul}-N-), 163.8 (COOH), 152.5 (C=N-[C]{.ul}=C-CO), 149.4 ([C]{.ul}=N-C=C-CO), 138.0(Ar-C), 136.0 (Ar-C), 130.0 (Ar-C), 128.8 (Ar-C), 128.7(Ar-C), 128.3 (Ar-C), 128.1 (Ar-C), 127.9 (CH~3~-[C]{.ul}=C), 123.8 (-C=[C]{.ul}-COOH), 58.8 (-[CH]{.ul}-S-), 57.6 ([CH]{.ul}(CO)-CH-S-), 57.1 (NH-[CH]{.ul}(CO)-Ph), 29.2 (-S-[CH~2~]{.ul}-), 19.8 (CH~3~). Anal. Calcd. for C~22~H~20~N~4~O~5~S: C, 58.40; H, 4.46; N, 12.38; S, 7.09; found: C, 58.63; H, 4.53; N, 12.61; S, 7.21.

*(6R,7R)-3-methyl-7-((R)-2-(3-nitrobenzamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4f**): Yellow microcrystals; yield: (0.43 g, 87%); m.p. 226--228 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 13.44 (s, 1H, COOH), 9.40 (d, *J* = 7.6 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 9.33 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH- ), 8.76--8.62 (m, 1H, Ar-H), 8.48--8.46 (m, 1H, Ar-H), 8.40--8.34 (m, 2H, Ar-H), 7.83--7.75 (m, 2H, Ar-H), 7.54 (d, *J* = 7.2 Hz, 1H, Ar-H), 7.39--7.30 (m, 2H, Ar-H), 5.91 (d, *J* = 7.6 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.67 (dd, *J* = 8.0, 4.8 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.00 (d, *J* = 4.8 Hz, 1H, -[CH]{.ul}-S-), 3.48 (d, *J* = 18.0 Hz, 1H, -S-[CH~2~]{.ul}-), 3.28 (d, *J* = 18.0 Hz, 1H, -S-[CH~2~]{.ul}-), 1.99 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.6 (CO-NH-CH[(CO)]{.ul}-Ph), 165.5 ([CO]{.ul}-NH-CH(CO)-Ph), 164.5 ([CO]{.ul}-N-), 163.6 (COOH), 147.60 ([C]{.ul}-NO~2~), 137.4(Ar-C), 135.4 (Ar-C), 134.4 (Ar-C), 132.5 (Ar-C), 130.5 (Ar-C), 129.9 (Ar-C), 128.3 (Ar-C), 127.3 (CH~3~-[C]{.ul}=C), 126.1 (Ar-C), 123.7(Ar-C), 122.7(-C=[C]{.ul}-COOH), 58.6 (-[CH]{.ul}-S-), 57.2 (NH-[CH]{.ul}(CO)-Ph), 56.9 ([CH]{.ul}(CO)-CH-S-), 28.9 (-S-[CH~2~]{.ul}-), 19.4 (CH~3~). Anal. Calcd. for C~23~H~20~N~4~O~7~S: C, 55.64; H, 4.06; N, 11.28; S, 6.46; found: C, 55.78; H, 4.03; N, 11.52; S, 6.52.

*(6R,7R)-3-methyl-8-oxo-7-((R)-2-phenyl-2-(3,4,5-trimethoxybenzamido)acetamido)-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4g**): *Yellow microcrystals; yield:* (0.49 g, 91%); m.p. 197--199 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.26 (d, *J* = 8.4 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.92 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.52 (d, *J* = 7.2 Hz, 2H, Ar-H ), 7.37--7.29 (m, 3H, Ar-H), 7.26 (s, 2H, Ar-H), 5.92 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.57 (dd, *J* = 8.4, 4.4 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 4.92 (d, *J* = 4.4 Hz, 1H, -[CH]{.ul}-S-), 3.83 (s, 6H, M-OCH~3~), 3.70 (s, 3H, P-OCH~3~), 3.39 (d, *J* = 20.0 Hz, 1H, -S-[CH~2~]{.ul}-), 3.14 (d, *J* = 20.0 Hz, 1H, -S-[CH~2~]{.ul}-), 1.93 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.8 (CO-NH-CH[(CO)]{.ul}-Ph), 165.8 ([CO]{.ul}-NH-CH(CO)-Ph), 164.0 ([CO]{.ul}-N-), 163.5 (COOH), 152.5 (m-OCH~3~-[C]{.ul}=), 140.2 (p-OCH~3~-[C]{.ul}=), 137.8 (Ar-C), 129.7 (Ar-C), 129.0 (Ar-C), 128.2 (Ar-C), 127.7 (Ar-C), 127.6 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 105.4 (Ar-C), 60.1 (-[CH]{.ul}-S-), 58.6 (P-O[C]{.ul}H~3~), 57.2 (NH-[CH]{.ul}(CO)-Ph), 56.7 ([CH]{.ul}(CO)-CH-S-), 56.1 (M-O[CH~3~]{.ul}), 28.9 (-S-[CH~2~]{.ul}-), 19.4 (CH[3]{.ul}). Anal. Calcd. for C~26~H~27~N~3~O~8~S: C, 57.66; H, 5.03; N, 7.76; S, 5.92; found: C, 57.94; H, 5.11; N, 7.88; S, 6.11.

*(6R,7R)-7-((R)-2-((S)-3-(1H-indol-3-yl)-2-(4-methylphenylsulfonamido)propanamido)-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4h**): Brown microcrystals; yield: (0.59 g, 86%); m.p. 125--127 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 12.56 (s, 1H, COOH), 10.76 (s, 1H, NH), 9.32 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.70 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 8.09 (d, *J* = 9.2 Hz, 1H, Ar-H), 7.91 (d, *J* = 8.4 Hz, 1H, Ar-H), 7.46 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.40 (d, *J* = 8.0 Hz, 1H, Ar-H), 7.30--7.24 (m, 4H, 3 Ar-H, 1H, N[H]{.ul}-SO~2~ ), 7.17 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.08--7.02 (m, 3H, Ar-H), 6.92 (t, *J* = 7.6, 1H, Ar-H), 5.68 (dd, *J* = 8.0, 4.0 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.58 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 4.98 (d, *J* = 4.0 Hz, 1H, -[CH]{.ul}-S-), 3.88 (dd, *J* = 8.4, 6.8 Hz, 1H, [CH]{.ul}-NH-SO~2~), 3.40 (d, *J* = 8.0 Hz, 1H, -S-[CH~2~]{.ul}-), 3.37 (d, *J* = 8.0 Hz, 1H, -S-[CH~2~]{.ul}-), 3.04 (dd, *J* = 14.4, 6.8 Hz, 1H, [CH~2~]{.ul}-CH-NH-SO~2~), 2.84 (dd, *J* = 14.4, 8.4 Hz, 1H, CH-NH-SO~2~), 2.31 (s, 3H, CH~3~), 2.00 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 172.6 (CO-NH-CH[(CO)]{.ul}-Ph), 170.3 ([CO]{.ul}-NH-CH(CO)-Ph), 163.9 ([CO]{.ul}-N-), 163.4 (COOH), 142.1 (SO~2~-[C]{.ul}=), 137.9 (Ar-C), 136.0 (Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 128.0 (Ar-C), 126.9 (Ar-C), 126.6 (Ar-C), 126.2 (Ar-C), 126.0 (CH~3~-[C]{.ul}=C), 123.9 (-C=[C]{.ul}-COOH), 120.7 (Ar-C), 120.6 (Ar-C), 118.3 (Ar-C), 117.7 (Ar-C), 111.3 (Ar-C), 108.8 (Ar-C), 64.83 (-[CH]{.ul}-S-), 57.18 ([CH]{.ul}(CO)-CH-S-), 56.76 (NH-[CH]{.ul}(CO)-Ph), 56.48 ([C]{.ul}H-NH-SO~2~), 28.61 ([CH~2~]{.ul}-CH-NH-SO~2~), 28.22 (-S-[CH~2~]{.ul}-), 20.88 ([CH~3~]{.ul}), 15.07 ([CH~3~]{.ul}). Anal. Calcd. for C~34~H~33~N~5~O~7~S~2~: C, 59.37; H, 4.84; N, 10.18; S, 9.32; found: C, 59.51; H, 4.89; N, 10.26; S, 9.46.

*(6R,7R)-3-methyl-7-((R)-2-(2-(4-methylphenylsulfonamido)benzamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid*(**4i**): White microcrystals; yield: (0.51 g, 82%); m.p. 137--139 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 13.16 (s, 1H, COOH), 11.07 (s, 1H, [NH]{.ul}SO~2~), 9.32 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 9.11 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.84 (d, *J* = 8.4 Hz, 1H, Ar-H), 7.67 (d, *J* = 8.4 Hz, 1H, Ar-H ), 7.59--7.26 (m, 10H, Ar-H), 7.15--7.10 (m, 1H, Ar-H), 5.81 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.68 (dd, *J* = 8.0, 4.0 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.01 (d, *J* = 4.0 Hz, 1H, -[CH]{.ul}-S-), 3.49 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 3.28 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 2.30 (s, 3H, CH~3~), 1.98 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.1 (CO-NH-CH[(CO)]{.ul}-Ph), 167.7 ([CO]{.ul}-NH-CH(CO)-Ph), 163.8 ([CO]{.ul}-N-), 163.4 (COOH), 137.0 (SO~2~-[C]{.ul}=), 129.7 (Ar-C), 129.7 (Ar-C), 129.5 (Ar-C), 129.4 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 127.7 (Ar-C), 126.7(Ar-C), 126.7 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 121.2 (Ar-C), 120.0 (Ar-C), 58.5 (-[CH]{.ul}-S-), 57.1 (NH-[CH]{.ul}(CO)-Ph), 56.6 ([CH]{.ul}(CO)-CH-S-), 28.8 (-S-[CH~2~]{.ul}-), 20.9 (CH~3~), 19.3 (CH~3~). Anal. Calcd. for C~30~H~28~N~4~O~7~S~2~: C, 58.05; H, 4.55; N, 9.03; S, 10.33; found: C, 58.31; H, 4.62; N, 9.14; S, 10.52.

*(6R,7R)-3-methyl-7-((R)-2-(4-methyl-2-(3,4,5-trimethoxybenzamido)thiazole-5-carboxamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4j**): Yellow microcrystals; yield: (0.61 g, 89%); m.p. 179--181 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.28 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.88 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.56 (s, 1H, NH), 7.52 (d, *J* = 7.2 Hz, 2H, Ar-H), 7.38--7.30 (m, 3H, Ar-H), 7.26 (s, 2H, Ar-H), 5.91 (d, *J* = 8.0 Hz, 1H, NH-[CH]{.ul}(CO)-Ph), 5.67 (dd, *J* = 8.0, 4.0 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.01 (d, *J* = 4.0Hz, 1H, -[CH]{.ul}-S-), 3.83 (s, 6H, m-OCH~3~), 3.71 (s, 3H, p-OCH~3~), 3.48 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 3.28 (d, *J* = 18.4 Hz, 1H, -S-[CH~2~]{.ul}-), 1.99 (s, 3H, CH~3~), 1.91 (s, 3H, CH~3~). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.8 (CO-NH-CH[(CO)]{.ul}-Ph), 165.7 (CO), 164.0 (CO), 163.4 (COOH), 152.8 (Ar-C), 152.4 (Ar-C), 140.2 (Ar-C), 137.7 (Ar-C), 129.8 (Ar-C), 128.9 (Ar-C), 128.2 (Ar-C), 127.6 (Ar-C), 127.6 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 122.7 (Ar-C), 105.4 (Ar-C), 60.0 (-[CH]{.ul}-S-), 58.5 (p-OCH~3~), 57.2 ([CH]{.ul}(CO)-CH-S-), 56.7 (NH-[CH]{.ul}(CO)-Ph), 56.0 (m-OCH~3~), 28.9 (-S-[CH~2~]{.ul}-), 21.0 (CH~3~), 19.3 (CH~3~). Anal. Calcd. for C~31~H~31~N~5~O~9~S~2~: C, 54.62; H, 4.58; N, 10.27; S, 9.41; found: C, 54.89; H, 4.61; N, 10.38; S, 9.5.

*(6R,7R)-3-methyl-7-((R)-2-(2-((S)-4-methylphenylsulfonamido)propanamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4k**): White microcrystals; yield: (0.53 g, 93%); m.p. 234--236 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.33 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.57 (d, *J* = 8.0 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 7.99 (s, 1H, NH-SO~2~), 7.65 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.39 (d, *J* = 7.6 Hz, 2H, Ar-H), 7.35--7.23 (m, 5H, Ar-H), 5.65 (dd, *J* = 8.0, 4.4 Hz, 1H, NH-[CH]{.ul}(CO)-CH-), 5.57 (d, *J* = 8.0 Hz, 1H NH-[CH]{.ul}(CO)-Ph), 4.95 (d, *J* = 4.4 Hz, 1H, -[CH]{.ul}-S-), 4.07--3.95 (m, 1H, NH-[CH]{.ul}-CH~3~), 3.44 (d, *J* = 18.0 Hz, 1H, -S-[CH~2~]{.ul}-), 3.23 (d, *J* = 18.0 Hz, 1H, -S-[CH~2~]{.ul}-), 2.39 (s, 3H, p-CH~3~), 1.97 (s, 3H, CH~3~), 1.03 (d, *J* = 6.8 Hz, 3H, NH-CH-[CH~3~]{.ul}).^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.8 ([CO]{.ul}-NH-CH(CO)-Ph), 170.4 (CO), 163.9 (CO), 163.4 (CO), 142.5 (Ar-C), 138.1(Ar-C), 137.8(Ar-C), 129.4 (Ar-C), 128.2 (Ar-C), 127.6 (Ar-C), 126.9 (Ar-C), 126.6 (Ar-C), 126.5 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 58.3 (-[CH]{.ul}-S-), 57.1 ([CH]{.ul}(CO)-CH-S-), 55.3 (NH-[CH]{.ul}(CO)-Ph), 51.7 (NH-[CH]{.ul}-CH~3~), 28.9 (-S-[CH~2~]{.ul}-), 21.0 (p-CH~3~), 19.4 (CH~3~), 18.9 (NH-CH-[CH~3~]{.ul}). Anal. Calcd. for C~26~H~28~N~4~O~7~S~2~: C, 54.53; H, 4.93; N, 9.78; S, 11.20; found: C, 54.80; H, 4.96; N, 9.88; S, 11.30.

*(6R,7R)-3-methyl-7-((R)-2-(2-((RS)-4-methylphenylsulfonamido)propanamido)-2-phenylacetamido)-8-oxo-5-thia-1-azabicyclo\[4.2.0\]oct-2-ene-2-carboxylic acid* (**4k**, **4k′**): White microcrystals; yield: (0.51 g, 89%); m.p. 224--227 °C; ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.35 (d, *J* = 7.6 Hz, 1H, [NH]{.ul}-CH(CO)-CH-), 8.57 (d, *J* = 7.6 Hz, 1H, [NH]{.ul}-CH(CO)-Ph), 8.01 (d, *J* = 8 Hz, 1H, NH-SO~2~), 7.72--7.58 (m, 2H, Ar-H), 7.45--7.22 (m, 7H, Ar-H), 5.73--5.62 (m, 1H, NH-[CH]{.ul}(CO)-CH-), 5.57 (d, *J* = 8.0 Hz, 1H NH-[CH]{.ul}(CO)-Ph), 5.46 (d, *J* = 7.6 Hz, 1H, -[CH]{.ul}-S-), 4.07--3.92 (m, 1H, NH-[CH]{.ul}-CH~3~), 3.45 (d, *J* = 17.2 Hz, 1H, -S-[CH~2~]{.ul}-), 3.27 (d, *J* = 17.2 Hz, 1H, -S-[CH~2~]{.ul}-), 2.36 (d, *J* = 15.6, 3H, p-CH~3~), 1.98 (s, 3H, CH~3~), 1.07--1.03 (m, 3H, NH-CH-[CH~3~]{.ul}). ^13^C-NMR (100 MHz, DMSO-*d*~6~) δ 170.8 ([CO]{.ul}-NH-CH(CO)-Ph (k)), 170.7 ([CO]{.ul}-NH-CH(CO)-Ph (k′)), 170.4 (CO), 163.9 (CO), 163.4 (CO), 142.6 (Ar-C (k′)), 142.5 (Ar-C (k)), 138.2(Ar-C (k′)), 138.1(Ar-C (k)), 137.8 (Ar-C), 129.9 (Ar-C (k)), 129.8 (Ar-C (k′)), 129.4 (Ar-C (k)), 129.3 (Ar-C (k′)), 128.2 (Ar-C), 126.9 (Ar-C), 126.6 (Ar-C), 126.5 (CH~3~-[C]{.ul}=C), 122.7 (-C=[C]{.ul}-COOH), 58.4 (-[CH]{.ul}-S-), 57.2 ([CH]{.ul}(CO)-CH-S-), 55.3 (NH-[CH]{.ul}(CO)-Ph), 51.7 (NH-[CH]{.ul}-CH~3~ (k)), 51.5 (NH-[CH]{.ul}-CH~3~ (k′)), 28.9 (-S-[CH~2~]{.ul}-), 21.0 (p-CH~3~ (k)), 20.9 (p-CH~3~ (k′)), 19.4 (CH~3~), 19.1 (NH-CH-[CH~3~]{.ul} (k)), 18.9 (NH-CH-[CH~3~]{.ul}(k)). Anal. Calcd. for C~26~H~28~N~4~O~7~S~2~: C, 54.53; H, 4.93; N, 9.78; S, 11.20; found: C, 54.77; H, 4.98; N, 9.86; S, 11.32.

2.2. Antimicrobial Activity {#sec2dot2-scipharm-84-00484}
---------------------------

### 2.2.1. Sensitivity Testing (Agar Diffusion Method) {#sec2dot2dot1-scipharm-84-00484}

Compounds (**4a**--**j**) and Cephalexin (Ceporex^®^) were dissolved in DMSO in the concentration 1 mg/mL. The microorganisms were cultivated overnight, and optical densities were adjusted 0.2--0.8 and diluted 1:100. Constructed compounds were tested against standard microbial strains in Mueller Hinton agar; Ceporex^®^ and DMSO were tested in parallel as a reference and negative control, respectively. Diameters of inhibition zones were measured in mm.

### 2.2.2. Minimum Inhibitory Concentration MIC (Broth Dilution Method) {#sec2dot2dot2-scipharm-84-00484}

Compounds (**4a-j**) and Cephalexin (Ceporex^®^) were dissolved in DMSO in the concentration 2 mg/mL as a stock solution and then diluted two-fold serially to 1 µg/mL in a Mueller Hinton broth (Sigma-Aldrich, Darmstadt, Germany). The microorganisms were cultivated overnight, and optical densities were adjusted to 0.2--0.8 and diluted 1:100. The constructed compounds were tested against the standard microbial strains; Ceporex^®^ and DMSO were tested in parallel as a reference and negative control, respectively.

3. Results and Discussion {#sec3-scipharm-84-00484}
=========================

3.1. Chemistry {#sec3dot1-scipharm-84-00484}
--------------

*N*-tosyl-[l]{.smallcaps}-tryptophan (**2h**), *N*-tosylanthranilic acid (**2i**), *N*-tosyl-[l]{.smallcaps}-alanine (**2k**), and *N*-tosyl-[dl]{.smallcaps}-alanine (**2k**, **2k′**) were prepared according to the reported procedure by the reaction of the corresponding amino acid with *p*-toluenesulfonyl chloride in the presence of triethylamine TEA \[[@B18-scipharm-84-00484]\]. The presence of the thiazole moiety in many cephalosporin antibiotics motivated us to synthesize 4-methyl-2-(3,4,5-trimethoxy benzamido)thiazole-5-carboxylic acid (**2j**) ([Scheme 1](#scipharm-84-00484-sch001){ref-type="scheme"}) \[[@B19-scipharm-84-00484]\]. Condensation of thiourea and ethyl-2-chloroacetoacetate gave ethyl 2-amino-4-methylthiazole-5-carboxylate (**5**) in 95% yield \[[@B20-scipharm-84-00484]\]. Compound (**5**) was then hydrolyzed using sodium hydroxide to give the free carboxylic acid (**6**) \[[@B21-scipharm-84-00484],[@B22-scipharm-84-00484]\]. Coupling of (**6**) with *N*-(3,4,5-trimethoxybenzoyl)benzotriazole (**3g**) afforded 4-methyl-2-(3,4,5-trimethoxybenzamido)thiazole-5-carboxylic acid (**2j**) in 90% yield.

*N*-acylbenzotriazoles **3a**--**k′** ([Scheme 2](#scipharm-84-00484-sch002){ref-type="scheme"}, [Table 1](#scipharm-84-00484-t001){ref-type="table"}) were prepared in 82%--96% yields via the reaction of carboxylic acids **2a**--**k′** with four equivalents of 1*H*-benzotriazole and one equivalent of SOCl~2~ in CH~2~Cl~2~ at 25 °C for 3 h \[[@B23-scipharm-84-00484]\]. Subsequently, *N*-acylbenzotriazoles **3a**--**j** and the racemic mixture **3k**, **3k′** were stirred with cephalexin sodium in acetonitrile for 6--20 h at 25 °C to afford *N*-acylcephalexins **4a**--**j** and the diastereomeric mixture **4k**, **4k′** in 82%--92% yield ([Scheme 2](#scipharm-84-00484-sch002){ref-type="scheme"}, [Table 1](#scipharm-84-00484-t001){ref-type="table"}). Novel *N*-acylbenzotriazoles **3h**--**k′** and *N*-acylcephalexins **4a**--**k′** were characterized by ^1^H-NMR, ^13^C-NMR, and elemental analysis. The diastereomeric mixture **4k**, **4k′** was prepared to confirm that the original chirality was maintained during the reaction of cephalexin with chiral *N*-acylbenzotriazoles under the current reaction conditions. The presence of strong absorption at 1764--1770 cm^−1^ in the IR spectra of **4a,b,d** and **g** confirmed that the β-lactam ring was not cleaved during coupling with *N*-acylbenzotriazoles.

3.2. Antimicrobial Activity {#sec3dot2-scipharm-84-00484}
---------------------------

Synthesized compounds **4a**--**j** were tested in vitro for their antimicrobial activity against *Staphylococcus aureus* (ATCC 6538), *Pseudomonas aeruginosa* (ATCC 27853), *Escherichia coli* (ATCC 10536), *Paenibacillus polymyxa* (ATCC 842), and *Candida albicans* (ATCC 10231). Cephalexin (Ceporex^®^) manufactured by: SmithKline Beecham, Harm-Giza, Egypt was used as a reference compound. Sensitivity testing (agar diffusion method) and MIC (broth microdilution method) were performed according to the reported method \[[@B26-scipharm-84-00484]\]. The antimicrobial activity of the test compounds as well as cephalexin sodium is depicted in [Table 2](#scipharm-84-00484-t002){ref-type="table"} and [Table 3](#scipharm-84-00484-t003){ref-type="table"} and ([Figure 2](#scipharm-84-00484-f002){ref-type="fig"}).

All the synthesized compounds **4a**--**j** showed antimicrobial activity against *S.aureus* comparable to Ceporex^®^. Furthermore, compounds **4c,e,g** exhibited bactericidal activity against *E. coli* (G-ve bacteria) and *P. polymyxa* (Gm+ve anaerobic bacteria) close to that of Ceporex^®^. The most interesting result was the strong antimicrobial activity of **4b,c,e,g** against the resistant strain of *P.aeruginosa* which was significantly higher than that of Ceporex^®^. *N*-nicotinylcephalexin (**4c**) and *N*-(3,4,5-trimethoxybenzoyl)cephalexin (**4g**) enjoyed a broader spectrum of antibacterial activity than cephalexin.

4. Conclusions {#sec4-scipharm-84-00484}
==============

In conclusion, we have utilized a mild and efficient protocol for acylating cephalexin as an example of cephalosporins containing amino nucleophiles using *N*-acylbenzotriazole methodology. The protocol described herein enabled the modulation of the antibacterial activity of cephalosporins. The preliminary antimicrobial susceptibility testing of the novel synthesized targets led to two promising cephalosporin antimicrobials with a broader spectrum of activity.
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Detailed NMR spectra are available online at <http://www.mdpi.com/2218-0532/84/3/484/s1>.
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Figures, Schemes and Tables
===========================

![Cephalexin.](scipharm-84-00484-g001){#scipharm-84-00484-f001}

![Synthesis of 4-methyl-2-(3,4,5-trimethoxybenzamido)thiazole-5-carboxylic acid (**2j**).](scipharm-84-00484-sch001){#scipharm-84-00484-sch001}

![Synthesis of target compounds *N*-acylcephalexins (**4a**--**k′**).](scipharm-84-00484-sch002){#scipharm-84-00484-sch002}

![Inhibition measured in mm.](scipharm-84-00484-g002){#scipharm-84-00484-f002}

scipharm-84-00484-t001_Table 1

###### 

RCO-, melting points (m.p.), and yields of *N*-acylbenzotriazoles **3a-k′** and *N*-acylcephalexines **4a-k′**.

  RCO-a--k′                         3a--k′ Yield %   3a--k′m.p. (°C) m.p. (°C) \[Lit.\]                 Time/h 4a--k′   4a--k′ Yield %   4a--k′ m.p. (°C)
  --------------------------------- ---------------- -------------------------------------------------- --------------- ---------------- ------------------
  ![](scipharm-84-00484-i001.jpg)   94               107--109 (106--108) \[[@B24-scipharm-84-00484]\]   10              87               210--212
  ![](scipharm-84-00484-i002.jpg)   95               150--153 (151--152) \[[@B24-scipharm-84-00484]\]   12              86               216--218
  ![](scipharm-84-00484-i003.jpg)   95               99--101 (100--101) \[[@B25-scipharm-84-00484]\]    12              84               168--170
  ![](scipharm-84-00484-i004.jpg)   94               111--112 (112--113) \[[@B14-scipharm-84-00484]\]   9               84               132--134
  ![](scipharm-84-00484-i005.jpg)   94               101--102 (101--102) \[[@B15-scipharm-84-00484]\]   8               82               200--202
  ![](scipharm-84-00484-i006.jpg)   90               156--157 (155--156) \[[@B16-scipharm-84-00484]\]   10              87               226--228
  ![](scipharm-84-00484-i007.jpg)   96               125--127 (126--128) \[[@B17-scipharm-84-00484]\]   6               91               197--199
  ![](scipharm-84-00484-i008.jpg)   87               175--176                                           12              86               125--127
  ![](scipharm-84-00484-i009.jpg)   89               148--150                                           12              82               137--139
  ![](scipharm-84-00484-i010.jpg)   82               107--110                                           20              89               179--181
  ![](scipharm-84-00484-i011.jpg)   90               142--144                                           14              93               234--236
  ![](scipharm-84-00484-i012.jpg)   90               142--144                                           14              89               224--227

scipharm-84-00484-t002_Table 2

###### 

Inhibition zones measured in mm for *N*-acylcephalexins **4a**--**j** and cephalexin (Ceporex^®^).

  Target        *Staphylococcus Aureus*   *Pseudomonas Aeruginosa*   *E. coli*   *Paenibacillus Polymyxa*
  ------------- ------------------------- -------------------------- ----------- --------------------------
  **4a**        27                        \-                         \-          \-
  **4b**        29                        17                         9           \-
  **4c**        30                        22                         20          25
  **4d**        29                        \-                         \-          \-
  **4e**        30                        20                         20          \-
  **4f**        32                        \-                         \-          21
  **4g**        30                        20                         21          26
  **4h**        30                        \-                         \-          \-
  **4i**        28                        \-                         \-          \-
  **4j**        30                        \-                         \-          8
  **Ceporex**   36 (S)                    5 (R)                      20 (S)      23 (S)

S: sensitive; R: resistance

scipharm-84-00484-t003_Table 3

###### 

Broth dilution method measured in µg/mL for *N*-acylcephalexins **4a**--**j** and cephalexin (Ceporex®).

  Target        *Staphylococcus Aureus*   *Pseudomonas Aeruginosa*   *E. coli*   *Paenibacillus Polymyxa*
  ------------- ------------------------- -------------------------- ----------- --------------------------
  **4a**        4                         \-                         \-          \-
  **4b**        2                         16                         \-          \-
  **4c**        ≤1                        8                          8           4
  **4d**        2                         \-                         \-          \-
  **4e**        ≤1                        8                          8           \-
  **4f**        ≤1                        \-                         \-          4
  **4g**        ≤1                        8                          4           4
  **4h**        ≤1                        \-                         \-          \-
  **4i**        2                         \-                         \-          \-
  **4j**        ≤1                        \-                         \-          \-
  **Ceporex**   ≤1 (S)                    \-                         8 (S)       4 (S)
